Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
I-MAB
(Name of Issuer)
Ordinary shares, par value US$0.0001 per share
(Title of Class of Securities)
44975P103**
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
o Rule 13d-1(c)
x Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Kaijing Yan |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
13,655,240 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
13,655,240 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
13,655,240 (1) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
8.3% (2) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
IN |
|
|
|
(1) Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science & Technology Development Co., Ltd. Tianjin Fuhuade Science & Technology Development Co., Ltd controls Tianjin Tasly Health Industry Investment Group Co., Ltd.. Tianjin Tasly Health Industry Investment Group Co., Ltd. controls Tasly Holding Group Co., Ltd.. Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.
(2) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tianjin Fuhuade Science & Technology Development Co., Ltd. |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
13,655,240 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
13,655,240 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
13,655,240 (3) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
8.3% (4) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(3) Tianjin Fuhuade Science & Technology Development Co., Ltd controls Tianjin Tasly Health Industry Investment Group Co., Ltd.. Tianjin Tasly Health Industry Investment Group Co., Ltd. controls Tasly Holding Group Co., Ltd.. Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.
(4) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tianjin Tasly Health Industry Investment Group Co., Ltd. |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
13,655,240 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
13,655,240 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
13,655,240 (5) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
8.3% (6) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(5) Tianjin Tasly Health Industry Investment Group Co., Ltd. controls Tasly Holding Group Co., Ltd.. Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.
(6) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tasly Holding Group Co., Ltd. |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
13,655,240 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
13,655,240 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
13,655,240 (7) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
8.3% (8) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(7) Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.
(8) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tasly Pharmaceutical Group Co., Ltd. |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
12,942,997 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
12,942,997 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
12,942,997 (9) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
7.8% (10) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(9) Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited is the record owner of 12,942,997 Ordinary Shares.
(10) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tasly Biopharmaceuticals Co., Ltd. |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
PRC |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
12,942,997 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
12,942,997 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
12,942,997 (11) |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
7.8% (12) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(11) Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited is the record owner of 12,942,997 Ordinary Shares.
(12) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tasly Biopharm Limited |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
British Virgin Islands |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
12,942,997 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
12,942,997 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
12,942,997 |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
7.8% (13) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(13) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
CUSIP No. 44975P103
|
1. |
Names of Reporting Persons. |
|
|
I.R.S. Identification Nos. of above persons (entities only). |
|
|
|
|
|
Tasly International BioInv One Limited |
|
|
|
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
(a) o |
|
|
(b) o |
|
|
|
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
|
|
|
4. |
Citizenship or Place of Organization |
|
|
|
|
|
Cayman Islands |
|
|
|
|
Number of |
5. |
Sole Voting Power |
|
|
712,243 | |
|
|
| |
|
6. |
Shared Voting Power | |
|
|
0 | |
|
|
| |
|
7. |
Sole Dispositive Power | |
|
|
712,243 | |
|
|
| |
|
8. |
Shared Dispositive Power | |
|
|
0 |
|
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
|
|
|
|
712,243 |
|
|
|
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares |
|
|
o |
|
|
|
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) |
|
|
|
|
|
0.4% (16) |
|
|
|
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
|
|
CO |
|
|
|
(16) The ownership percentage of the Reporting Person is calculated based on 165,477,620 ordinary shares outstanding (excluding 4,036,868 ordinary shares issued to the deposit bank of I-Mab for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the share incentive plans of I-Mab). as reported to be outstanding in the Company’s Form 424(B)(5) filed with the Securities Exchange Commission on February 9, 2021.
Item 1.
(a) Name of Issuer:
I-MAB
(b) Address of Issuer’s Principal Executive Offices:
Suite 802, West Tower, OmniVision
88 Shangke Road, Pudong District
Shanghai, 201210
People’s Republic of China
Item 2.
(a) Name of Person Filing:
I. Kaijing Yan
II. Tianjin Fuhuade Science & Technology Development Co., Ltd.
III. Tianjin Tasly Health Industry Investment Group Co., Ltd.
IV. Tasly Holding Group Co., Ltd.
V. Tasly Pharmaceutical Group Co., Ltd.
VI. Tasly Biopharmaceuticals Co., Ltd.
VII. Tasly Biopharm Limited
VIII. Tasly International BioInv One Limited
(b) Address of Principal Business Office or, if none, Residence:
I, II, III, IV & V.
Tasly-TCM Garden
No. 2 Pujihe East Road
Beichen district, Tianjin
P.R.China.
VI. & VII.
Building 1&2, No. 280, Juli Road
China (Shanghai) Pilot Free Trade Zone
P.R.China.
VIII.
Room 2302, 23/F, Far East Finance Center
16 Harcourt Road, Admiralty
Hong Kong
(c) Citizenship:
I, II, III, IV, V. &VI People’s Republic of China
VII. British Virgin Islands
VIII. Cayman Islands
(d) Title of Class of Securities:
Ordinary shares, par value of $0.0001 per share
(e) CUSIP Number:
44975P103
There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares(“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.
Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
Not applicable
Item 4. Ownership
(a) Amount beneficially owned:
The information required by Items 4(a) is set forth in Row 9 of the cover page for each Reporting Person and is incorporated herein by reference.
(b) Percent of class:
The information required by Items 4(a) is set forth in Row 11 of the cover page for each Reporting Person and is incorporated herein by reference.
(c) Number of shares as to which the person has:
The information required by Items 4(c) is set forth in Rows 5-8 of the cover page for each Reporting Person and is incorporated herein by reference.
Kaijing Yan is the controlling shareholder of Tianjin Fuhuade Science & Technology Development Co., Ltd. Tianjin Fuhuade Science & Technology Development Co., Ltd controls Tianjin Tasly Health Industry Investment Group Co., Ltd.. Tianjin Tasly Health Industry Investment Group Co., Ltd. controls Tasly Holding Group Co., Ltd.. Tasly Holding Group Co., Ltd. controls Tasly Pharmaceutical Group Co., Ltd. and Tasly International BioInv One Limited. Tasly Pharmaceutical Group Co., Ltd. controls Tasly Biopharmaceuticals Co., Ltd.. Tasly Biopharmaceuticals Co., Ltd. is the sole shareholder of Tasly Biopharm Limited. Tasly Biopharm Limited and Tasly International BioInv One Limited are the record owner of 12,942,997 Ordinary Shares and the record owner of 712,243 Ordinary Shares.
Item 5. Ownership of Five Percent or Less of a Class
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable
Item 8. Identification and Classification of Members of the Group
Not applicable
Item 9. Notice of Dissolution of Group
Not applicable
Item 10. Certifications
Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 16, 2021
|
|
Kaijing YAN | |
|
|
| |
|
|
/S/ Kaijing YAN | |
|
|
| |
|
|
| |
|
|
Tianjin Fuhuade Science & Technology Development Co., Ltd. | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: General Manger |
|
|
|
|
|
|
|
|
|
|
Tianjin Tasly Health Industry Investment Group Co., Ltd. | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: Director |
|
|
|
|
|
|
|
|
|
|
Tasly Holding Group Co., Ltd. | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: Director |
|
|
|
|
|
|
|
|
|
|
Tasly Pharmaceutical Group Co., Ltd. | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: Chairman of the Board of Directors |
|
|
|
|
|
|
|
|
|
|
Tasly Biopharmaceuticals Co., Ltd. | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: Chairman of the Board of Directors |
|
|
|
|
|
|
|
|
|
|
Tasly Biopharm Limited | |
|
|
| |
|
|
| |
|
|
By: |
/S/ Kaijing YAN |
|
|
|
Name: Kaijing YAN |
|
|
|
Title: Director |